Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure

The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of AVP secretion) in HF is unknown.

[1]  J. Díez.  Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy , 2016, European journal of heart failure.

[2]  G. Leng,et al.  Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random Numbers , 2016, Journal of neuroendocrinology.

[3]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[4]  J. Daubert,et al.  Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study , 2015, Open Heart.

[5]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[6]  C. Yancy,et al.  Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial , 2013, Circulation: Heart Failure.

[7]  R. Wachter,et al.  Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: results from the CIBIS-ELD trial. , 2012, Clinical biochemistry.

[8]  J. Rehfeld,et al.  Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. , 2011, JAMA.

[9]  A. Houng,et al.  Decompensated Heart Failure Is Associated With Reduced Corin Levels and Decreased Cleavage of Pro–Atrial Natriuretic Peptide , 2011, Circulation. Heart failure.

[10]  T. Miyamoto,et al.  Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  N. Morgenthaler,et al.  Copeptin: a biomarker of cardiovascular and renal function. , 2010, Congestive heart failure.

[12]  R. Kronmal,et al.  Left Ventricular Mass: Allometric Scaling, Normative Values, Effect of Obesity, and Prognostic Performance , 2010, Hypertension.

[13]  J. Struck,et al.  Gender and renal function influence plasma levels of copeptin in healthy individuals. , 2009, Clinical science.

[14]  J. Struck,et al.  Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.

[15]  M. Konstam,et al.  Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia , 2008, Circulation.

[16]  M. Kurabayashi,et al.  Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. , 2008, European heart journal.

[17]  J. Gottdiener,et al.  Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. , 2008, European heart journal.

[18]  Yan-hong Fan,et al.  Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. , 2007, Life sciences.

[19]  M. Kronenberg,et al.  Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. , 2007, Journal of the American College of Cardiology.

[20]  S. Kjeldsen,et al.  Arterial Plasma Vasopressin and Aldosterone Predict Left Ventricular Mass in Men Who Develop Hypertension Over 20 Years , 2007, Journal of clinical hypertension.

[21]  K. Chatterjee.  Neurohormonal activation in congestive heart failure and the role of vasopressin. , 2005, The American journal of cardiology.

[22]  J. Granton,et al.  Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology , 2003, Critical care.

[23]  K. Kikuchi,et al.  Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor , 1999, Molecular and Cellular Biochemistry.

[24]  S. Takishita,et al.  Non-corresponding effects of an angiotensin-converting enzyme inhibitor on cardiac and vascular hypertrophy in spontaneously hypertensive rats. , 2000, Hypertension research : official journal of the Japanese Society of Hypertension.

[25]  E. Simon,et al.  Inhibition of vasopressin and aldosterone release by atrial natriuretic peptide in conscious rabbits , 1992, Experimental physiology.

[26]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[27]  M. Condorelli,et al.  Impaired control of vasopressin release in hypertensive subjects with cardiac hypertrophy. , 1987, Hypertension.